Page last updated: 2024-09-05

deferasirox and Cytokine Release Syndrome

deferasirox has been researched along with Cytokine Release Syndrome in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Birlutiu, RM; Birlutiu, V; Chicea, L1

Other Studies

1 other study(ies) available for deferasirox and Cytokine Release Syndrome

ArticleYear
Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
    Medicine, 2021, May-07, Volume: 100, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Comorbidity; COVID-19 Drug Treatment; Cytokine Release Syndrome; Deferasirox; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Off-Label Use; Pneumonia, Viral; Respiration, Artificial; Retrospective Studies; Romania; SARS-CoV-2

2021
chemdatabank.com